Strata Critical Medical, Inc. (SRTA) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SRTA Revenue Growth
Revenue Breakdown (FY 2025)
SRTA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
SRTA Revenue Analysis (2019–2025)
As of May 8, 2026, Strata Critical Medical, Inc. (SRTA) generated trailing twelve-month (TTM) revenue of $210.2 million, reflecting exceptional growth of +24.1% year-over-year. The most recent quarter (Q1 2026) recorded $67.4 million in revenue, up 196.4% sequentially.
Looking at the longer-term picture, SRTA's 5-year compound annual growth rate (CAGR) stands at +53.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $248.7 million in 2024.
Revenue diversification analysis shows SRTA's business is primarily driven by Logistics (90%), and Clinical (10%). With over half of revenue concentrated in Logistics, the company maintains significant focus in this area while developing other growth vectors.
When compared to Industrials sector peers including ENSG (+19.2% YoY), ADUS (+19.6% YoY), and CCRN (-39.5% YoY), SRTA has outperformed the peer group in terms of revenue growth. Compare SRTA vs ENSG →
SRTA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SRTACurrent | $210M | +24.1% | +53.1% | -11.3% | |
 ENSG | $5.1B | +19.2% | +16.1% | 8.6% | |
 ADUS | $1.4B | +19.6% | +13.2% | 9.7% | |
 CCRN | $1.1B | -39.5% | +4.7% | -0.3% | |
 AMN | $2.7B | +19.9% | +2.7% | 1.2% | |
 TBI | $1.6B | -18.8% | -2.6% | -1.7% |
SRTA Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $197.1M | -20.7% | $41.1M | 20.9% | $-22,353,000 | -11.3% |
| 2024 | $248.7M | +10.4% | $58.9M | 23.7% | $-33,926,000 | -13.6% |
| 2023 | $225.2M | +54.1% | $42.1M | 18.7% | $-68,117,000 | -30.3% |
| 2022 | $146.1M | +189.2% | $22.3M | 15.2% | $-53,529,000 | -36.6% |
| 2021 | $50.5M | +115.6% | $10.5M | 20.8% | $-24,093,000 | -47.7% |
| 2020 | $23.4M | -24.9% | $2.3M | 9.9% | $-10,359,000 | -44.2% |
| 2019 | $31.2M | - | $4.7M | 15.1% | $-11,541,000 | -37.0% |
See SRTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SRTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SRTA vs SPIR
Side-by-side business, growth, and profitability comparison vs Spire Global, Inc..
Start ComparisonSRTA — Frequently Asked Questions
Quick answers to the most common questions about buying SRTA stock.
Is SRTA's revenue growth accelerating or slowing?
SRTA revenue is accelerating at +24.1% year-over-year, exceeding the 5-year CAGR of +53.1%. TTM revenue reached $210M. Growth momentum has increased versus prior periods.
What is SRTA's long-term revenue growth rate?
Strata Critical Medical, Inc.'s 5-year revenue CAGR of +53.1% reflects the sustained expansion pattern. Current YoY growth of +24.1% is above this long-term average.
How is SRTA's revenue distributed by segment?
SRTA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.